Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 77-83

  Tanhäuserová, Veronika ^a   Kuricov́a, Katarína ^a   Pácal, Lukáš ^a   Bartáková, Vendula ^a   Řehoŕová, Jitka ^b   Svojanovský, Jan ^c   Olšovský, Jindřich ^c   Bìlobrádková, Jana ^b   Kaòková, Kateřina ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

advanced glycation end products; diabetic nephropathy; fructosamine 3 kinase; glyoxalase; pentose phosphate pathway; transketolase

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; FRUCTOSAMINE; FRUCTOSAMINE 3 KINASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYOXALASE; GLYOXALASE 1; INSULIN; TRANSALDOLASE; TRANSALDOLASE LIKE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLYCATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLISM; MICROALBUMINURIA; MIDDLE AGED; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TRANSKETOLASE;

EID: 84891427717     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0833     Document Type: Article

References (16)

1. Thomas MC, Groop PH, Tryggvason K. Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens 2012;21:195-202.
2. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2007;2:1306-16.
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70.
4. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-9.
5. Pacal L, Tomandl J, Svojanovsky J, Krusova D, Stepankova S, Rehorova J, et al. Role of thiamine status and genetic variability in transketolase and other pentose phosphate cycle enzymes in the progression of diabetic nephropathy. Nephrol Dial Transplant 2011;26:1229-36.
6. Coy JF, Dubel S, Kioschis P, Thomas K, Micklem G, Delius H, et al. Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 1996;32:309-16.
7. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006;94:578-85.
8. Delpierre G, Van Schaftingen E. Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochem Soc Trans 2003;31:1354-7.
9. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, Van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32:31-9.
10. Krautwald M, Munch G. Advanced glycation end products as biomarkers and gerontotoxins-A basis to explore methylglyoxal-lowering agents for Alzheimer's disease? Exp Gerontol 2010;45:744-51.
11. Barua M, Jenkins EC, Chen W, Kuizon S, Pullarkat RK, Junaid MA. Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity-implications for autism. Autism Res 2011;4:262-70.
12. Engelen L, Ferreira I, Brouwers O, Henry RM, Dekker JM, Nijpels G, et al. Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies. J Hypertens 2009;27:1399-403.
13. Wu JC, Li XH, Peng YD, Wang JB, Tang JF, Wang YF. Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. J Endocrinol Invest 2011;34:e343-8.
14. Junaid MA, Kowal D, Barua M, Pullarkat PS, Sklower Brooks S, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A 2004;131:11-7.
15. Mohas M, Kisfali P, Baricza E, Merei A, Maasz A, Cseh J, et al. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c Levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118:209-12.
16. Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2164-70.